Allogene Therapeutics ALLO

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.17 (+8.42%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Allogene Therapeutics (ALLO)
    Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.18

    • Market Cap

      $457.09 Million

    • Price-Earnings Ratio

      -1.41

    • Total Outstanding Shares

      209.67 Million Shares

    • Total Employees

      361

    • Dividend

      No dividend

    • IPO Date

      October 11, 2018

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      210 east grand avenue, South san francisco, CA, 94080

    • Homepage

      https://www.allogene.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$111.09 Million
    Net Cash Flow From Investing Activities, Continuing$88.22 Million
    Net Cash Flow From Financing Activities, Continuing$111.09 Million
    Net Cash Flow$-18.01 Million
    Net Cash Flow From Operating Activities$-217.31 Million
    Net Cash Flow From Operating Activities, Continuing$-217.31 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Revenues$43,000
    Operating Income/Loss$-297.82 Million
    Benefits Costs and Expenses$283.47 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Basic Earnings Per Share$-1.55
    Income/Loss From Continuing Operations After Tax$-283.43 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-280.86 Million
    Comprehensive Income/Loss$-280.86 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$2.57 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Equity Attributable To Noncontrolling Interest$0
    Equity$463.75 Million
    Noncurrent Liabilities$92.80 Million
    Cash$403.40 Million
    Assets$589.12 Million
    Other Current Liabilities$27.07 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALLO from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.